Results 161 to 170 of about 23,391 (181)

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Lancet, The, 2008
Josef S Smolen, Andrea Rubbert-Roth, César R Ramos-Remus   +2 more
exaly  

Interleukin-22: Immunobiology and Pathology

Annual Review of Immunology, 2015
Jarrod A Dudakov, Alan Hanash, Marcel R M Van Den Brink   +2 more
exaly  

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

New England Journal of Medicine, 1987
W M Linehan
exaly  

Interleukin-1beta.

Critical care medicine, 2006
openaire   +1 more source

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Philip J Mease, Bruce W Kirkham, Arthur Kavanaugh   +2 more
exaly  

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Carla J Greenbaum   +2 more
exaly  

Interleukin-1beta induction of matrix metalloproteinase-9 increases endothelial permeability

Journal of the American College of Surgeons, 2010
Homer Haygood Keadle, Heidi J. Haun, Lingwei Kong, Jing Kang, Joe S. Robinson, Don Nakayama, Zhongbiao Wang   +6 more
openaire   +1 more source

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

New England Journal of Medicine, 2012
Claus Otto Carl Zachariae
exaly  

Estrogen and interleukin-1beta regulation of trophinin, osteopontin, cyclooxygenase-1, cyclooxygenase-2, and interleukin-1beta system in the porcine uterus.

Society of Reproduction and Fertility supplement, 2010
F J, White, E M, Kimball, G, Wyman, D R, Stein, J W, Ross, M D, Ashworth, R D, Geisert   +6 more
openaire   +1 more source

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
Geert D'Haens, Julian Panes, Arthur Kaser   +2 more
exaly